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INTRODUCTION
A fundamental mechanism for the maintenance of
glucose homeostasis is the rapid action of insulin to
stimulate glucose uptake and metabolism in peripheral
tissues. Skeletal muscle is the primary site of glucose
disposal in the insulin-stimulated state [1]. Resistance to
the actions of insulin in skeletal muscle is a major pathogenic
factor in type 2 or type 1 diabetes mellitus [2,3]; it also
contributes to the morbidity of obesity, and complicates
poorly controlled type 1 (autoimmune) diabetes [2]. The
ability of insulin to increase glucose transport in skeletal
muscle is elicited by the translocation of glucose transporter
4 (Glut4), the major insulin regulated glucose transporter,
from intracellular vesicles to the plasma membrane and
transverse tubules [4]. In muscle of type 2 diabetic subjects,
the expression of the Glut4 gene is normal, and impaired
glucose uptake by insulin action most likely results from
altered trafficking or impaired function of Glut4 [5-7].
Because glucose transport in response to other stimuli
that use different signaling pathways is normal in
muscle of type 2 diabetic subjects [4], the resistance to
insulin stimulation may be due to impaired insulin signal
transduction [8]. In this review, we mainly summarize
the updated information on insulin signaling over the
past decade, with particular emphasis on the molecular
mechanism of human insulin resistance, and also address
the physiological role of the newly identified player of
insulin action. 
Insulin receptor signaling
Insulin signaling involves a cascade of events initiated
by insulin binding to its cell surface receptor, followed by
receptor autophosphorylation, and activation of receptor
tyrosine kinases, which result in tyrosine phosphorylation
of insulin receptor substrates (IRSs) including IRS1, IRS2,
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REVIEWIRS3, IRS4, Gab1, and Shc [9,10]. Binding of IRSs to the
regulatory subunit of phosphoinositide 3-kinase (PI3K)
via Src homology 2 (SH2) domains results in activation of
PI3K, which phosphorylates membrane phospholipids
and phosphatidylinositol 4,5-bisphosphate (PIP2) on the
3’ position. This complex activates the 3-phosphoinositide-
dependent protein kinases (PDK-1 and PDK-2) resulting
in activation of Akt/protein kinase B (PKB) and atypical
protein kinase C λ and ζ, (PKCλ/ζ), each of which are
serine/threonine kinases [11,12]. Activated Akt phos-
phorylates its 160 kDa substrate (AS160), which
stimulates the translocation of insulin-mediated Glut4
from intracellular vesicles to the plasma membrane [13].
Moreover, activation of PKCλ/ζ is also involved in the
regulation of Glut4 translocation in response to insulin
[14,15]. However, the insulin receptor (IR) is also
dephosphorylated and inactivated by protein tyrosine
phosphatases (PTPs), which comprise an extensive family
of proteins that exert negative effects on insulin action
and glucose metabolism [16,17]. In addition, phosphatase
and tension homologue deleted on chromosome 10
(PTEN), a lipid phosphatase, serves as an important
negative modulator for the insulin signaling pathway
by hydrolyzing phosphatidylinositol 3,4,5-triphosphate
to PIP2, antagonizing the PI3K pathway [18,19]. Thus,
the physiological regulation of insulin action is controlled
by the balance between phosphorylation and dephos-
phorylation (Fig. 1). Most importantly, the PI3K pathway
is thought to be a key component of  the insulin signaling
cascade, which is necessary for the metabolic effects of
insulin on glucose transport and Glu4 translocation
[20,21]. Indeed, insulin-stimulated PI3K activity
decreases in skeletal muscle of type 2 diabetic subjects
[8,22], providing evidence for a defect in insulin signaling
that could contribute to impaired Glut4 translocation and
insulin resistance. 
Role of Akt in insulin signaling
The serine/threonine kinase Akt is a downstream
mediator of PI3K [12]. Three Akt isoforms have been
cloned [23,24]; Akt1, Akt2, and Akt3, all of which are
ubiquitously expressed in the tissues. Insulin has
differential effects on Akt isoforms in a tissue-, isoform-,
and species-specific manner [25,26]. In obese rats,
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Figure 1. The insulin signaling pathway. PTP1B, protein-tyrosine phosphatase 1B; IRS, insulin receptor substrate; ROCK, Rho-kinase;
PIP, phosphatidylinositol phosphate; PTEN, phosphatase and tension homologue deleted on chromosome 10; PH domain, pleckstrin
homology domain; PDK, phosphoinositide-dependent protein kinase; GβL, G-protein beta subunit like; mTOR, mammalian target of
rapamycin; AS160, 160 kDa Akt substrate; PKCλ/ζ , protein kinase C λ and ζ; Glut4, glucose transporter 4.
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insulin-stimulated Akt1 activity decreases in muscle and
adipose tissue but increases in liver, while insulin-
stimulated Akt2 activity decreases in muscle and liver but
increases in adipose tissue [25]. Some studies have shown
that inhibition of Akt activation by DN-Akt expression has
no significant effect on insulin-stimulated glucose
transport, whereas Akt siRNA inhibits insulin-stimulated
glucose transport in 3T3-L1 adipocytes [27]. Furthermore,
in skeletal muscles from insulin-resistant models, including
PTP-1B transgenic mice [28], leukocyte antigen-related
phosphatase (LAR) transgenic mice [29], and glucosamine-
infused rats [30], insulin-induced Akt activation is normal
but insulin-stimulated glucose uptake is impaired. In
skeletal muscle of obese insulin resistant humans with or
without type 2 diabetes, the effect of insulin on the activity
of all Akt isoforms in muscle in vivo is normal [8]. However,
at very high insulin levels in vitro, Akt activity is diminished
in muscle from non-obese type 2 diabetics [31]. Moreover,
Akt2 phosphorylation is impaired in adipocytes from
obese type 2 diabetics [32]. Whether these impairments in
Akt1 or Akt2 activity are sufficient to play a role in insulin
resistant states is unclear. Akt1 knockout mice do not have
insulin resistance, although their growth retardation or
developmental effects could mask this [33]. Akt2 knockout
mice have impaired insulin action on liver and modest
effects in muscle and adipocytes that could possibly be
secondary to the liver defect [34]. In this regard, our
studies have also demonstrated that insulin-stimulated
Akt activity in skeletal muscle of these obese rats is very
mildly reduced while PI3K activity is markedly reduced, as
compared to lean rats [25]. These data lead us to propose
the hypothesis that full activation of PI3K is not necessary
to maximally activate Akt, and that other pathways that
are independent of PI3K are also involved in activation of
Akt by insulin, at least in insulin resistant states. Data in
support of the hypothesis come from studies showing that
insulin-stimulated PI3K activation is reduced by 50% to
60% while Akt activation is normal in hepatoma cells
transduced with a dominant-interfering mutant of dynamin
[35]. Conceivably, such pathways could be induced in
altered metabolic states such as obesity or type 2 diabetes.
Thus, the potential impact of altered Akt activity in
insulin-dependent glucose metabolism remains uncertain.
This important issue can be resolved by studying an
animal model that has Akt selectively deleted in peripheral
tissues. Until now, there are no data regarding the effects
of tissue-specific deletion of Akt on glucose metabolism
and insulin signaling. 
AS160 is an Akt substrate involved in Glut4
translocation
Investigation of steps down-stream of Akt could shed
light on the role of Akt in insulin resistance. Akt directly
phosphorylates cytosol proteins that have the RXRXXS/T
motif. Using a phosphospecific antibody that only recognizes
serine or threonine residues, which are phosphorylated by
Akt [36], the Lienhard group has discovered the AS160
from 3T3-L1 adipocytes. This molecule was originally
named TBC1 domain family member 4 (TBC1D4) and
contains two phosphotyrosine binding (PTB) domains at
the NH2 terminus and a Rab GTPase activating protein
(GAP) domain at the COOH terminus [37]. In the basal
state of 3T3-L1 adipocytes, AS160 was mainly localized in
the low density microsomes (LDM) fraction. However,
upon insulin stimulation, it was redistributed from the
LDM compartment to the cytosol, but these effects were
significantly blocked by treatment with a PI3K inhibitor
[36]. Given that one of the LDM components are vesicles
containing the glucose transporter Glut4 [38], and they
move to and fuse with the plasma membrane in response
to insulin [39], it is conceivable that AS160 may be involved
in the process of GLUT4 trafficking that is dependent on
PI3K signaling. The Lienhard group further demonstrated
the important role of AS160 in the regulation of Glut4
translocation by showing that insulin causes a marked
increase in AS160 phosphorylation at Ser318, Ser570,
Ser588, Thr642, and Thr751 residues, and that mutation of
these sites inhibits Glut4 translocation in response to
insulin [13]. Support for this finding comes from skeletal
muscle studies showing that insulin stimulates AS160
phosphorylation in skeletal muscle in a PI3K-dependent
fashion, and that contraction and the AMP-activated
protein kinase (AMPK) activator aminoimidazole
carboxamide ribonucleotide (AICAR) also increases AS160
phosphorylation in isolated rat epitrochlearis muscle and
other muscle systems [40-44]. Moreover, in skeletal
muscle of human insulin-resistant subjects, including
those with polycystic ovary syndrome and type 2 diabetes,
the ability of insulin to increase AS160 phosphorylation is
significantly impaired [45,46]. Collectively, the current
available data provide important evidence that insulin-
stimulated phosphorylation of AS160 is required to
regulate Glut4 translocation, which is a critical step in
controlling glucose homeostasis, and that decreased
insulin-induced AS160 phosphorylation in skeletal muscle
may play an important role in insulin resistance in vivo.  Role of PKCλ λ/ζ ζ in the regulation of insulin-mediated
glucose transport
The atypical PKC isoforms λ and ζ, are downstream
PI3K mediators, and their activation is required for insulin
stimulation of glucose uptake [47-49]. Overexpression of
a dominant negative mutant of PKCλ or PKCζ abrogates
insulin-stimulated glucose transport and Glut4
translocation in adipose [47,50] and muscle cells [48,49].
Overexpression of constitutively active PKCλin adipocytes
[47] or wildtype PKCζ in muscle in vivo [51] enhances
both basal and insulin-stimulated glucose transport. In
addition, PKCλ and ζ appear to function interchangeably,
as overexpression of wild type PKCλrestores the inhibitory
effects of a dominant negative mutant of PKCζ on insulin-
stimulated Glut4 translocation, and vice versa [52]. The
possibility that PKCλ/ζ could play an important role in
insulin resistance in vivo is supported by studies showing
impaired insulin-stimulated PKCλ/ζ activity in skeletal
muscle and adipose tissue of non-obese type 2 diabetic GK
rats [53,54]. Moreover, insulin-stimulated PKCλ/ζactivity
decreases in cultured myotubes of obese humans with
impaired glucose tolerance [55] and in muscle of obese
diabetic monkeys [56]. Along with these findings, the
Farese group have demonstrated that muscle-specific
deletion of PKCλ/ζ causes insulin resistance by reducing
insulin-mediated glucose transport in skeletal muscle [15].
Importantly, insulin-stimulated PKCλ/ζ activity is
reduced in the muscle of obese nondiabetic and obese type
2 diabetic subjects. This contrasts with our findings that
Akt activation is normal in obese and diabetic subjects
with similar metabolic characteristics [8]. Thus, although
insulin-induced PI3K activity is reduced in type 2 diabetic
subjects, not all downstream pathways are similarly
affected. These data imply that reduced insulin-stimulated
atypical PKC activity may play an important role in insulin
resistance in vivo. 
Insulin-sensitizer agents and insulin signaling
Thiazolidinediones (TZDs) are a new class of insulin-
sensitizing agents being used for the treatment of type 2
diabetes [57]. The molecular targets of these compounds
are thought to include the nuclear receptor, peroxisome
proliferator activator receptor-γ (PPARγ), which regulates
the expression of numerous genes that affect glucose and
lipid metabolism [58]. Evidence suggests that TZDs
ameliorate insulin resistance in humans primarily by
increasing insulin-stimulated glucose disposal in skeletal
muscle [59]. Our previous studies revealed that treatment
with troglitazone, a member of the TZD family, increases
insulin-stimulated IRS-1-associated PI3K activity and Akt
activity in skeletal muscle of type 2 diabetic patients [60].
The troglitazone effect on PI3K activity was associated
with an increase in the amount of the p110β catalytic
subunit of PI3K [60]. Consistently, enhanced Akt
phosphorylation was also detected in skeletal muscle in
normal, glucose-tolerant, insulin-resistant, first-degree
relatives of type 2 diabetic patients [61]. These findings
suggest that the mechanism for the insulin-sensitizing
effect of TZDs could involve enhanced PI3K activation in
skeletal muscle of obese type 2 diabetic subjects. However,
Karsson et al. [62] demonstrated that insulin action on
Akt phosphorylation and PI3K activity is unaltered in
skeletal muscle of human subjects with newly diagnosed
type 2 diabetes after treatment of rosiglitazone, another
member of the TZD family. This discrepancy could be due
to either the nature of the human subjects (obese type 2
diabetic vs. lean type 2 diabetic) or the different kinds of
TZDs. From the view of the current human data, it is
somewhat unlikely that changes in insulin signaling can
fully account for the improvement of insulin sensitivity
and glucose disposal in skeletal muscle in response to TZD
treatment. 
Given that correlative changes in fatty acid metabolism
and improvements in glucose homeostasis and insulin
sensitivity may imply an indirect effect on skeletal muscle
via adipose tissue [63,64], it is possible that some of the
effects of TZDs on insulin signaling work through
secondary mechanisms. One potential factor is fatty acids,
as elevations of fatty acids in plasma and the lipid content
of muscle are associated with insulin resistance [65]. As
previously reported [66,67], troglitazone treatment tends
to lower triglyceride and free fatty acid concentrations.
TZDs also reduce accumulation of muscle triglycerides
and diacylglycerol [68]. Activation of PKC by elevated
diacylglycerol levels in muscle impairs insulin signaling
[69,70]. This raises the possibility that decreases in
plasma lipid concentrations with TZD treatment could
lead to a reduction of diacylglycerol in muscle, reducing
PKC activation, resulting in an improvement of the insulin
signaling cascade. It is also possible that TZDs reduce
intramyocellular lipid content by promoting storage of
free fatty acids in adipocyte triglycerides via PPARγ,
redirecting free fatty acids from skeletal muscle to adipose
tissue. Thus, the ability of troglitazone to improve insulin
action in skeletal muscle could involve actions on both
adipose tissue and muscle.
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Metformin is a member of another class of drugs that
are effective in lowering glucose concentrations in patients
with type 2 diabetes [71]. A number of studies have
demonstrated that metformin inhibits gluconeogenesis,
reduces hepatic glucose output, and lowers fasting blood
glucose concentration [59,72]. In addition to its effect on
the liver, metformin also appears to decrease glucose
concentrations by increasing peripheral insulin sensitivity
and augmenting insulin-mediated glucose uptake in
skeletal muscle of type 2 diabetic subjects [73]. The precise
mechanism for this action of metformin is incompletely
understood, but in vitro studies indicate it could involve
multiple effects, including increased translocation of Glut1
and Glut4 glucose transporters from intracellular vesicles
to the cell surface [74] and increased binding of insulin to
cell surface insulin receptors [75]. Evidence shows that
metformin normalizes insulin receptor tyrosine
phosphorylation and PI3K and Akt activity in adipocytes
exposed to high insulin levels in vitro for long periods
[76]. However, our studies have demonstrated that the
effects of metformin on PI3K and Akt activity in skeletal
muscle of human insulin resistant subjects with obesity
and type 2 diabetes in vivo are unchanged [60]. These
data are further confirmed in skeletal muscle of patients
with newly diagnosed type 2 diabetes [62]. Overall, it is
clear that enhanced insulin-mediated glucose disposal
by metformin therapy in type 2 diabetic patients is
independent of improved insulin signaling in skeletal
muscle of type 2 diabetic subjects.
Effects of weight loss therapy on skeletal muscle
insulin signaling
Given that obesity is the major risk factor for developing
insulin resistance, it is no doubt that lifestyle intervention
that produces weight loss, improves insulin sensitivity. A
reduction of fat mass by weight loss results in a significant
decrease in lipid oxidation and an enhanced glucose
homeostasis [77]. In addition, insulin secretion and
plasma insulin concentrations decrease significantly
after weight loss. Our work has investigated whether
weight loss therapy can alter the ability of insulin to
activate PI3K and downstream signaling in skeletal
muscle of obese nondiabetic patients. For these studies,
ten obese nondiabetic subjects (body mass index [BMI],
30 to 45 kg/m2) were challenged on a very low calorie diet
(VLCD) of 600 to 800 calories per day for up to 24 weeks
or until 10 to 15% of initial body weight was lost [78]. Once
the weight loss goal was met, the subjects were introduced
to a weight-maintenance diet. Glucose disposal rate
measured by euglycemic hyperinsulinemic clamp was
increased by 30% after VLCD treatment, indicating
enhanced systemic insulin sensitivity. VLCD treatment
significantly increased IRS-1 tyrosine phosphorylation,
compared with the pretreatment level [78]. In parallel,
insulin-stimulated IRS-1-associated PI3K activity was
increased 2-fold post-treatment with VLCD, compared
with pretreatment [78]. These changes were independent
of the total amount of IRS-1 protein. Importantly, the
impaired PKCλ/ζ activation in obese nondiabetic humans
was reversed with weight reduction. This could be due to
increased signaling upstream of PKCλ/ζ. This, combined
with the observation that treating diabetic subjects with
TZDs reverses the defect in PKCλ/ζ activity [79], suggests
that reversal of the PKCλ/ζ defect might enhance insulin
sensitivity in obese insulin-resistant humans. In line with
these findings, recent studies of severely obese individuals
also demonstrated that weight loss with a very low energy
diet (1,883 kJ/day) markedly enhances insulin sensitivity
by improving insulin-stimulated glucose disposal [77].
This enhanced sensitivity was accompanied by increased
insulin signaling at the level of AS160 and proline-rich Akt
substrate 40, which is a component of the mammalian
target of the rapamycin nutrient-sensing pathway. Taken
together, weight reduction in obese individuals improves
insulin sensitivity, which may result from an improvement
in PI3K and its downstream signaling in skeletal muscle.
Although our studies have not investigated Glut4
translocation in response to insulin in skeletal muscle of
obese subjects that have undergone weight loss, a number
of studies have demonstrated that enhancement in the
insulin signaling pathway was not accompanied by a
significant improvement in Glut4 translocation to the
plasma membrane in skeletal muscle from type 2 diabetic
patients, TZD-treated type 2 diabetic patients, and obese
subjects who underwent gastric bypass surgery
[62,80,81]. This could be explained by the fact that
intrinsic activity of Glut4 at the plasma membrane is
increased or that an unidentified glucose transporter,
which may contribute to increased glucose disposal in
skeletal muscle, is involved in this event. 
Protein tyrosine phosphatase 1B and insulin
signaling
Tyrosine phosphorylation of the IR is reversible, and IR
dephosphorylation takes place rapidly in intact cells even
with the continued presence of insulin [82]. Because acritical regulatory step in insulin signal transduction is the
dephosphorylation of signaling molecules by PTPs, it is
plausible that enhanced activity of one or more PTPs
could lead to insulin resistance. Several studies of obese
humans and rodents have reported that the expression
and/or activity of specific PTPs, including the trans-
membrane LAR and the intracellular enzymes protein-
tyrosine phosphatase 1B (PTP1B) and Src-homology 2
domain-containing phosphatase-2 (SHP2, SHPTP2, or
syp), increase in muscle and adipose tissue [83-87]. LAR
and PTP1B show the greatest increases (3-fold in muscle,
2-fold in fat) [83,88]. There is a strong correlation
between BMI and total PTP activity toward the IR in both
skeletal muscle and adipose tissue from lean and obese
subjects [83,88]. Recent studies have also observed
increased levels of LAR and PTP1B expression in liver and
muscle from obese rodents [89]. 
Support for the role of PTPs in the regulation of insulin
action comes from transgenic and gene knockout studies.
The Kahn group generated PTP1B null mice by targeted
disruption of the ATG-coding exon [90]. Elchebly et al.
[91] targeted exons 5 and 6 (Ex5/6 -/-) and also obtained
PTP1B-null mice. Both lines of mice have increased insulin
sensitivity, manifested by enhanced insulin-stimulated
phosphorylation of IR and IRS-1 in muscle and liver.
PTP1B-deficient mice have reduced body fat and are
protected from diet-induced obesity due, at least in
part, to increased basal metabolic rate and total energy
expenditure [90]. In addition, insulin-stimulated whole-
body glucose disposal is enhanced in PTP1B-deficient
mice [90]. Surprisingly, this effect is tissue-specific;
insulin-stimulated glucose uptake is elevated in skeletal
muscle but not in adipose tissue. These data suggest that
overexpression of PTP1B in insulin-target tissues in vivo
could contribute to insulin resistance. Consistent with
this hypothesis, Zabolotny et al. [28] demonstrated that
selective overexpression of PTP1B in skeletal muscle
impairs insulin-stimulated PI3K activity and causes mild
insulin resistance in vivo. Moreover, recent studies have
indicated that liver-specific deletion of PTP1B improves
insulin resistance and attenuates diet-induced endoplasmic
reticulum stress [92]. Similar to these findings, Haj et al.
[93] showed that liver-specific re-expression of PTP1B
in PTP1B deficient mice leads to marked attenuation of
their enhanced insulin sensitivity. In obese diabetic
insulin resistant ob/ob and db/db mice, PTP1B antisense
oligonucleotide (ASO) treatment reduces PTP1B protein
and mRNA level in liver and fat, and normalizes plasma
glucose levels along with improved glucose tolerance and
insulin sensitivity [94,95]. Taken together, the current
data indicate that inhibition of PTP1B in peripheral tissues
may be useful for treating metabolic-related disorders
such as obesity and type 2 diabetes. In fact, the development
of PTP1B inhibitors has received much attention by the
pharmaceutical industry. However, it has been difficult to
identify a selective, safe, and effective PTP1B inhibitor,
although a novel PTP1B inhibitor (JTT-551) has been
suggested as a potential therapeutic agent [96].
Rho-kinase and IRS-1 serine phosphorylation
Rho-kinase (ROCK) is a serine/threonine protein kinase
identified as a GTP-Rho-binding protein [97]. There are
two isoforms, ROCK1 (also known as ROKβ) [98,99] and
ROCK2 (also known as ROKα) [98,100]. ROCK par-
ticipates in the insulin signaling network by interacting
with IRS-1 [101,102]. Our work has demonstrated that
inhibiting ROCK decreases insulin-stimulated IRS-1-
associated PI3K activity in adipocytes and myotubes. This
effect is mainly due to decreased tyrosine phosphorylation
of the YXXM motif in IRS-1, which can lead to reduced
interaction of IRS-1 with the p85 subunit of PI3K. Indeed,
insulin-stimulated IRS-1 binding to the p85 regulatory
subunit of PI3K is impaired in adipocytes expressing
dominant negative ROCK [103]. By mass spectrometry
analysis, we identified the serine residues of IRS-1 at
serine 632/635, serine 936, and serine 972, all of which
are phosphorylated by ROCK. Interestingly, these sites are
close to the YMXM motif domain in IRS-1, which is the
binding site of the p85 regulatory subunit of PI3K.
Evidence indicates that serine phosphorylation of IRS-1 is
a key regulator of insulin signaling [104]. However, the
effects of phosphorylation of individual IRS-1 serine
residues on insulin signaling appear to be complex and
may be context dependent; they are still being defined.
Studies of the effects of IRS-1 serine 632/635
phosphorylation on insulin action have yielded conflicting
results. Our studies have demonstrated that replacing IRS
serines 632 and 635 with alanine causes a significant
inhibition of insulin-stimulated IRS-1 tyrosine
phosphorylation and PI3K activity [103], suggesting a
positive role for IRS-1 serine 632/635 in insulin action. 
Our recent studies have demonstrated that global
deletion of ROCK1 in mice results in whole-body insulin
resistance and impaired skeletal muscle insulin signaling.
These effects are independent of changes in body adiposity.
Insulin-stimulated IRS-1 serine 632/635 phosphorylation
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and PI3K activity associated with IRS-1 or phosphotyrosine
are impaired in skeletal muscle of ROCK1 deficient mice
[105]. Impaired insulin-induced IRS-1 serine 632/635
phosphorylation also accompanies decreased PI3K and
ROCK activation in skeletal muscle of obese, insulin-
resistant or diabetic mice and rats (unpublished data),
suggesting that impaired IRS-1 serine 632/635 phos-
phorylation may be an important mechanism contributing
to the pathogenesis of insulin resistance in obesity. In
addition, insulin-stimulated ROCK activity is impaired in
skeletal muscle of obese diabetic mice and insulin-
resistant humans with obesity and type 2 diabetes
(unpublished data). Importantly, insulin-stimulated
ROCK1 activity was positively correlated with glucose
disposal rate, suggesting that defective ROCK1 activation
may contribute to the pathogenesis of human insulin
resistance. Thus, our studies identify ROCK1 as a novel
player regulating insulin-mediated glucose metabolism
in vivo. Further studies of ROCK1 and ROCK2 functions
in different metabolic tissues will be needed to precisely
delineate ROCK isoform functions that regulate tissue and
whole-body insulin sensitivity and glucose homeostasis.
The emergence of ROCK1 as an important regulator of
insulin action could lead to new treatment approaches for
obesity and type 2 diabetes.
CONCLUSION
The earliest defect in the development of type 2 diabetes
is insulin resistance characterized by decreased glucose
transport and metabolism in skeletal muscle. Studies with
the skeletal muscle of type 2 diabetic humans demonstrate
impaired insulin activation of the IRS-1/PI3K/Akt
signaling pathway, which is a critical step in the regulation
of glucose transport in response to insulin. These defects
are selectively restored by treatment with an insulin-
sensitizing agent and lifestyle changes, representing
the core of insulin signaling components. Recent advances
have also revealed that insulin action on AS160 phos-
phorylation is diminished in skeletal muscle of type 2
diabetic patients, and that inhibiting AS160 causes a
significant decrease in insulin-dependent translocation of
Glut4, suggesting an important role for AS160 in glucose
metabolism. Furthermore, defective ROCK activity in
skeletal muscle may also contribute to impaired glucose
homeostasis in type 2 diabetic patients. A better
understanding of the disease pathogenesis and the
potential alternative pathways for regulating glucose
metabolism could lead to new therapeutic targets for
obesity and type 2 diabetes by clarifying intracellular
defects in the insulin signaling cascade.
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